chemotherapy-induced neuropathy
Conditions
Interventions
None listed
Sponsors
Maxima Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • Written informed consent • Patients aged > 18 years • All cancer patients starting with paclitaxel, docetaxel or oxaliplatin • Understand Dutch language
Exclusion criteria
Exclusion criteria: • Patients with reported pre-existing neuropathy • Patients with cold intolerance • Patients with Raynaud*s syndrome • Patients earlier treated with paclitaxel, docetaxel or oxaliplatin • Patients using scalp cooling • Short-term chemoradiation with paclitaxel, docetaxel or oxaliplatin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main study parameters/endpoints: Quality of life and neuropathy symptoms are measured with the validated European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORCT-QLQ) and with the validated CIPN20 self-report questionnaire respectively at four time points (begin study, after three cycles, end of chemotherapy and after 6 months). | — |
Secondary
| Measure | Time frame |
|---|---|
| Secundary objectives of the study are; 1) The degree of tolerance for the use of the frozen gloves measured with the numering rating scale (NRS) 2) Dose reduction due to neurotoxicity. 3) Difference in neurotoxicity expressed in the common toxicity criteria (CTC). 4) Clustering of symptoms: do patients also have complaints in the feet and are these similar to complaints of the hands? | — |
Countries
Netherlands
Outcome results
None listed